B. Kilgallen

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Daniel J. Wallace, Kenneth Kalunian, Michelle Petri et al. · Annals of the Rheumatic Diseases · 2013 · 338 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

Megan E. B. Clowse, Daniel J. Wallace, Richard Furie et al. · Arthritis & Rheumatology · 2016 · 236 citations · Full text

Life Sciences, Clinical Sciences, Immunology +17

Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up

Daniel J. Wallace, Caroline Gordon, Vibeke Strand et al. · Lara D. Veeken · 2013 · 129 citations · Full text

Medicine, Immunology, Pharmacology +17

A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis

Atul Deodhar, Lianne S. Gensler, Jonathan Kay et al. · Arthritis & Rheumatology · 2019 · 101 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +12

Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006

Vibeke Strand, Michelle Petri, Kenneth Kalunian et al. · Lara D. Veeken · 2013 · 68 citations

Pharmacy, Pharmacology, Pharmacotherapy +16